Related Experiment Video
Updated: Nov 20, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Nanopore Identification of Single Nucleotide Mutations in Circulating Tumor DNA by Multiplexed Ligation
Nitza Burck1, Tal Gilboa1,2,3, Abhilash Gadi4
1Department of Biomedical Engineering, Technion- IIT, Haifa, Israel.
Background:
Circulating tumor DNAs (ctDNAs) are highly promising cancer biomarkers, potentially applicable for noninvasive liquid biopsy and disease monitoring. However, to date, sequencing of ctDNAs has proven to be challenging primarily due to small sample size and high background of fragmented cell-free DNAs (cfDNAs) derived from normal cells in the circulation, specifically in early stage cancer.
Methods:
Solid-state nanopores (ssNPs) have recently emerged as a highly efficient tool for single-DNA sensing and analysis. Herein, we present a rapid nanopore genotyping strategy to enable an amplification-free identification and classification of ctDNA mutations. A biochemical ligation detection assay was used for the creation of specific fluorescently-labelled short DNA reporter molecules. Color conjugation with multiple fluorophores enabled a unique multi-color signature for different mutations, offering multiplexing potency. Single-molecule readout of the fluorescent labels was carried out by electro-optical sensing via solid-state nanopores drilled in titanium oxide membranes.
Results:
As proof of concept, we utilized our method to detect the presence of low-quantity ERBB2 F310S and PIK3Ca H1047R breast cancer mutations from both plasmids and xenograft mice blood samples. We demonstrated an ability to distinguish between a wild type and a mutated sample, and between the different mutations in the same sample.
Conclusions:
Our method can potentially enable rapid and low cost ctDNA analysis that completely circumvents PCR amplification and library preparation. This approach will thus meet a currently unmet demand in terms of sensitivity, multiplexing and cost, opening new avenues for early diagnosis of cancer.
Insights
This study introduces a nanopore genotyping method for rapid, amplification-free detection of circulating tumor DNA (ctDNA) mutations. The technique successfully identified specific breast cancer mutations in samples, paving the way for improved early cancer diagnosis.
Area of Science:
- Biotechnology
- Molecular Biology
- Genomics
Background:
- Circulating tumor DNAs (ctDNAs) are valuable cancer biomarkers for noninvasive liquid biopsies.
- Detecting ctDNAs is challenging due to low concentrations and high background from normal cell-free DNAs (cfDNAs), especially in early-stage cancer.
Purpose of the Study:
- To develop a rapid, amplification-free nanopore genotyping strategy for ctDNA mutation identification and classification.
- To enable sensitive and multiplexed detection of ctDNA mutations for early cancer diagnosis.
Main Methods:
- Utilized solid-state nanopores (ssNPs) for single-DNA sensing.
- Employed a ligation detection assay with multi-color fluorescent labels to create unique mutation signatures.
- Performed single-molecule electro-optical sensing via ssNPs for readout.
Main Results:
- Successfully detected low-quantity ERBB2 F310S and PIK3Ca H1047R breast cancer mutations from plasmids and xenograft mouse blood.
- Demonstrated the ability to distinguish between wild-type and mutated samples.
- Showed capability to differentiate between distinct mutations within the same sample.
Conclusions:
- The developed nanopore method offers rapid, low-cost ctDNA analysis, bypassing PCR amplification and library preparation.
- Addresses unmet needs in ctDNA analysis for sensitivity, multiplexing, and cost-effectiveness.
- Opens new possibilities for early cancer diagnosis through advanced liquid biopsy techniques.
More Related Videos
11:02Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
Published on: October 18, 2013
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016